Recombinant COVID-19 Vaccine
Prevention of COVID-19
Phase 3Clinical
Key Facts
About Tiantan Bio
Tiantan Bio is a major player in China's biopharmaceutical sector, with a core focus on plasma-derived therapeutics and vaccines. As part of the Sinopharm Group ecosystem, it benefits from significant scale and strategic importance in public health. The company leverages its extensive plasma collection network and manufacturing capabilities to serve the large domestic market, with a pipeline that includes both biosimilars and novel biological products.
View full company profileTherapeutic Areas
Other Prevention of COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| Recombinant COVID-19 Vaccine (ZF2001) | Zhifei Biological Products | Approved |
| Novel Coronavirus mRNA Vaccine | Zhifei Biological Products | Clinical |
| COVID-19 Inactivated Vaccine (BBIBP-CorV) | Tiantan Bio | Approved |
| MVA-BN (Multi-Variant) | Bavarian Nordic | Phase 2 |
| Oral COVID-19 Vaccine | Oramed Pharmaceuticals | Pre-clinical |
| DMAb-1 | Inovio Pharmaceuticals | Phase 1 |
| DMAb-2 | Inovio Pharmaceuticals | Phase 1 |
| SARS-CoV-2 Vaccine | Auro Vaccines | Poised for Clinical |